|
![]() |
|
|
Glucotrol: profile and news
Local ties assist new Pfizer drug Feb 20, 2006 Pfizer's Exubera(R): A Unique Background Perspective Jan 27, 2006 Andrx Corporation Reports 2005 Third Quarter Results Nov 8, 2005 Karen A. Dawes Elected a Director of Repligen Corporation Sep 15, 2005 FDA panel backs drug for Type 2 diabetes Sep 12, 2005 New drug can reduce blood sugar Sep 19, 2005 Many meds don't mix with the sun Sep 21, 2005 'A LIFE SAVER': PROGRAM MAKES DRUGS MORE AVAILABLE Aug 19, 2005 A TRUSS CAN BE A TEMPORARY FIX FOR A HERNIA Jul 23, 2005 Should cancer patient wear truss for hernia? Jul 28, 2005 Top 10 Things to Know About Diabetes Pills Jul 4, 2005 A prescription for helping Jun 28, 2005 Daily drug regimen of Alice and Ken Heckman Apr 16, 2005 Industry's biggest manufacturers enter generics through loophole Apr 10, 2005 BCBSNC Launches New Prescription Drug Savings Initiative Feb 17, 2005 Other information Indication For the treatment of hyperglycemia in Non-insulin-dependent diabetes mellitus (NIDDM) Pharmacology Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. Mechanism Of Action Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Drug Category Hypoglycemic Agents; ATC:A10BB07 Brand Names/Synonyms AC-120; Aldiab; Apamid; CHEMBANK72; Digrin; Dipazide; G117; Glibenese; Glibetin; Glican; Glide; Glidiab; Glipid; Glipizida [Inn-Spanish]; Glipizide; Glipizide Extended-Release Tablets; Glipizide [Usan:Ban:Inn]; Glipizidum [Inn-Latin]; Gluco-Rite; Glucolip; Glucotrol; Glucotrol Xl; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; K 4024; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Sucrazide; TK 1320 Dosage Forms IR oral tablets and ER oral tablets Absorption uniform, rapid, and essentially complete Interactions -->Interactions for Glipizide: Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81). Chemical IUPAC Name N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-pyridine-2-carboxamide Chemical Formula C22H28N4O4S Half Life 2-4 hours Drug Type Approved Drug # Accession No APRD00436 CAS Registry Number 29094-61-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |